Talaris Therapeutics is a biotechnology business based in the US. Talaris Therapeutics shares (TALS) are listed on the NASDAQ and all prices are listed in US Dollars. Talaris Therapeutics employs 84 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $2.83 |
| 200-day moving average | $2.44 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.74 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -22.81% |
| Return on equity TTM | -41.64% |
| Profit margin | 0% |
| Book value | $34.88 |
| Market Capitalization | $119.6 million |
TTM: trailing 12 months
We're not expecting Talaris Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Talaris Therapeutics's shares were split on a 1:10 basis on 19 October 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Talaris Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Talaris Therapeutics shares which in turn could have impacted Talaris Therapeutics's share price.
Over the last 12 months, Talaris Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Talaris Therapeutics's is 2.1789. This would suggest that Talaris Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Talaris Therapeutics's beta into context you can compare it against those of similar companies.
As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc. , in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Access remote advice, planning and portfolio management from this established financial services company.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2025.
A deep dive into the highlights and limitations of Robinhood.
This account boasts commission-free trades and no minimums but has a low cash sweep rate.